Wiki-Pi

Search Results for: Diabetes

3097 interactions found:

Sort by: Relevance Number of Pathways Number of Drugs Number of Diseases
Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
AR and IDE androgen receptor insulin-degrading enzyme
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
  • Levonorgestrel
  • Spironolactone
  • Flutamide
  • Oxandrolone
  • Testosterone
  • Nilutamide
  • Fludrocortisone
  • Drostanolone
  • Nandrolone phenpropionate
  • Bicalutamide
  • Fluoxymesterone
  • Drospirenone
  • Danazol
  • Testosterone Propionate
  • Delta1-dihydrotestosterone
  • Boldenone
  • Calusterone
  • Flufenamic Acid
  • Dihydrotestosterone
  • (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
  • Methyltrienolone
  • (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
  • Cyproterone
  • Methyltestosterone
  • 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
  • (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
  • 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
  • (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
  • 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
  • (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
  • (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
  • (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
  • S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
  • 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
  • 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
  • 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
  • 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
  • Nandrolone decanoate
  • Enzalutamide
  • Insulin Regular
  • Insulin, porcine
  • Bacitracin
AR and SRC androgen receptor SRC proto-oncogene, non-receptor tyrosine kinase
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
  • Signaling by ERBB2
  • Levonorgestrel
  • Spironolactone
  • Flutamide
  • Oxandrolone
  • Testosterone
  • Nilutamide
  • Fludrocortisone
  • Drostanolone
  • Nandrolone phenpropionate
  • Bicalutamide
  • Fluoxymesterone
  • Drospirenone
  • Danazol
  • Testosterone Propionate
  • Delta1-dihydrotestosterone
  • Boldenone
  • Calusterone
  • Flufenamic Acid
  • Dihydrotestosterone
  • (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
  • Methyltrienolone
  • (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
  • Cyproterone
  • Methyltestosterone
  • 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
  • (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
  • 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
  • (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
  • 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
  • (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
  • (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
  • (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
  • S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
  • 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
  • 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
  • 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
  • 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
  • Nandrolone decanoate
  • Enzalutamide
  • Dasatinib
  • RU84687
  • RU79256
  • N6-Benzyl Adenosine-5\'-Diphosphate
  • RU85493
  • RU78262
  • Phosphonotyrosine
  • Malonic acid
  • RU83876
  • RU90395
  • RU79072
  • RU78783
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • PASBN
  • RU82129
  • PAS219
  • DPI59
  • RU82197
  • Phenylphosphate
  • RU78300
  • RU79073
  • RU82209
  • ISO24
  • RU85053
  • RU78299
  • Oxalic Acid
  • RU78191
  • Citric Acid
  • RU81843
  • 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
  • Purvalanol A
  • Bosutinib
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
  • 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
  • N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
  • (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
  • Ponatinib
AR and TCF4 androgen receptor transcription factor 4
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
  • CDO in myogenesis
  • Myogenesis
  • Levonorgestrel
  • Spironolactone
  • Flutamide
  • Oxandrolone
  • Testosterone
  • Nilutamide
  • Fludrocortisone
  • Drostanolone
  • Nandrolone phenpropionate
  • Bicalutamide
  • Fluoxymesterone
  • Drospirenone
  • Danazol
  • Testosterone Propionate
  • Delta1-dihydrotestosterone
  • Boldenone
  • Calusterone
  • Flufenamic Acid
  • Dihydrotestosterone
  • (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
  • Methyltrienolone
  • (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
  • Cyproterone
  • Methyltestosterone
  • 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
  • (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
  • 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
  • (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
  • 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
  • (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
  • (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
  • (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
  • S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
  • 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
  • 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
  • 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
  • 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
  • Nandrolone decanoate
  • Enzalutamide
AR and TBP androgen receptor TATA box binding protein
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
  • RNA Polymerase II Promoter Escape
  • RNA Polymerase III Transcription Initiation From Type 3 Promoter
  • RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
  • RNA Polymerase I Chain Elongation
  • RNA Polymerase II Transcription
  • RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
  • RNA Polymerase I Transcription Initiation
  • RNA Polymerase I Promoter Clearance
  • HIV Infection
  • RNA Polymerase II Pre-transcription Events
  • HIV Life Cycle
  • HIV Transcription Initiation
  • NoRC negatively regulates rRNA expression
  • RNA Polymerase II HIV Promoter Escape
  • RNA Polymerase III Transcription Initiation
  • RNA Polymerase III Transcription
  • RNA Polymerase III Transcription Initiation From Type 1 Promoter
  • RNA Polymerase I Transcription
  • RNA Polymerase I Transcription Termination
  • RNA Polymerase I Promoter Escape
  • Epigenetic regulation of gene expression
  • Negative epigenetic regulation of rRNA expression
  • Late Phase of HIV Life Cycle
  • RNA Polymerase III Transcription Initiation From Type 2 Promoter
  • RNA Polymerase II Transcription Initiation And Promoter Clearance
  • RNA Polymerase III Abortive And Retractive Initiation
  • RNA Polymerase II Transcription Initiation
  • SIRT1 negatively regulates rRNA Expression
  • Transcription of the HIV genome
  • Levonorgestrel
  • Spironolactone
  • Flutamide
  • Oxandrolone
  • Testosterone
  • Nilutamide
  • Fludrocortisone
  • Drostanolone
  • Nandrolone phenpropionate
  • Bicalutamide
  • Fluoxymesterone
  • Drospirenone
  • Danazol
  • Testosterone Propionate
  • Delta1-dihydrotestosterone
  • Boldenone
  • Calusterone
  • Flufenamic Acid
  • Dihydrotestosterone
  • (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
  • Methyltrienolone
  • (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
  • Cyproterone
  • Methyltestosterone
  • 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
  • (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
  • 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
  • (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
  • 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
  • (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
  • (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
  • (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
  • S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
  • 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
  • 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
  • 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
  • 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
  • Nandrolone decanoate
  • Enzalutamide
TRIM23 and CREB5 tripartite motif containing 23 cAMP responsive element binding protein 5
ARF1 and INSR ADP-ribosylation factor 1 insulin receptor
  • Synthesis of PIPs at the Golgi membrane
  • Metabolism of lipids and lipoproteins
  • Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
  • HIV Infection
  • Golgi Associated Vesicle Biogenesis
  • Host Interactions of HIV factors
  • The role of Nef in HIV-1 replication and disease pathogenesis
  • Clathrin derived vesicle budding
  • Lysosome Vesicle Biogenesis
  • Golgi to ER Retrograde Transport
  • MHC class II antigen presentation
  • COPI Mediated Transport
  • Phospholipid metabolism
  • trans-Golgi Network Vesicle Budding
  • Nef Mediated CD4 Down-regulation
  • Adaptive Immune System
  • PI Metabolism
  • Insulin receptor signalling cascade
  • IRS activation
  • Signal attenuation
  • IRS-related events
  • SHC-related events
  • Insulin receptor recycling
  • SHC activation
  • Signaling by Insulin receptor
  • Insulin Regular
  • Insulin Lispro
  • Insulin Glargine
  • Insulin, porcine
  • Mecasermin
  • Insulin Aspart
  • Insulin Detemir
  • Insulin Glulisine
  • Adenosine-5\'-[Beta, Gamma-Methylene]Triphosphate
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
  • Insulin, isophane
ARF1 and AP3S2 ADP-ribosylation factor 1 adaptor-related protein complex 3, sigma 2 subunit
  • Synthesis of PIPs at the Golgi membrane
  • Metabolism of lipids and lipoproteins
  • Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
  • HIV Infection
  • Golgi Associated Vesicle Biogenesis
  • Host Interactions of HIV factors
  • The role of Nef in HIV-1 replication and disease pathogenesis
  • Clathrin derived vesicle budding
  • Lysosome Vesicle Biogenesis
  • Golgi to ER Retrograde Transport
  • MHC class II antigen presentation
  • COPI Mediated Transport
  • Phospholipid metabolism
  • trans-Golgi Network Vesicle Budding
  • Nef Mediated CD4 Down-regulation
  • Adaptive Immune System
  • PI Metabolism
ARF5 and AP3B1 ADP-ribosylation factor 5 adaptor-related protein complex 3, beta 1 subunit
  • Golgi Associated Vesicle Biogenesis
  • trans-Golgi Network Vesicle Budding
  • Clathrin derived vesicle budding
ARF5 and ARFIP1 ADP-ribosylation factor 5 ADP-ribosylation factor interacting protein 1
ARF5 and IKBKG ADP-ribosylation factor 5 inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma
  • Signaling by the B Cell Receptor (BCR)
  • Downstream TCR signaling
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • RIP-mediated NFkB activation via ZBP1
  • Toll Like Receptor TLR6:TLR2 Cascade
  • IRAK1 recruits IKK complex
  • Downstream signaling events of B Cell Receptor (BCR)
  • Activated TLR4 signalling
  • Toll Like Receptor TLR1:TLR2 Cascade
  • FCERI mediated NF-kB activation
  • MyD88 cascade initiated on plasma membrane
  • Toll Like Receptor 5 (TLR5) Cascade
  • ZBP1(DAI) mediated induction of type I IFNs
  • NOD1/2 Signaling Pathway
  • MyD88 dependent cascade initiated on endosome
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88:Mal cascade initiated on plasma membrane
  • Toll Like Receptor 9 (TLR9) Cascade
  • IRAK1 recruits IKK complex
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • Innate Immune System
  • activated TAK1 mediates p38 MAPK activation
  • TRIF-mediated TLR3/TLR4 signaling
  • MAP kinase activation in TLR cascade
  • IKK complex recruitment mediated by RIP1
  • Cytosolic sensors of pathogen-associated DNA
  • Cytokine Signaling in Immune system
  • MyD88-independent cascade
  • Toll Like Receptor 2 (TLR2) Cascade
  • Signaling by Interleukins
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • TCR signaling
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
  • Activation of NF-kappaB in B cells
  • Toll Like Receptor 3 (TLR3) Cascade
  • Toll Like Receptor 4 (TLR4) Cascade
  • Fc epsilon receptor (FCERI) signaling
  • Interleukin-1 signaling
  • TRAF6 mediated NF-kB activation
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Adaptive Immune System
ARF5 and GGA1 ADP-ribosylation factor 5 golgi-associated, gamma adaptin ear containing, ARF binding protein 1
ARF5 and ASAP2 ADP-ribosylation factor 5 ArfGAP with SH3 domain, ankyrin repeat and PH domain 2
ARF5 and RAB11FIP3 ADP-ribosylation factor 5 RAB11 family interacting protein 3 (class II)
  • Cargo trafficking to the periciliary membrane
  • Organelle biogenesis and maintenance
  • VxPx cargo-targeting to cilium
  • Assembly of the primary cilium
ARF5 and PIP5K1A ADP-ribosylation factor 5 phosphatidylinositol-4-phosphate 5-kinase, type I, alpha
  • Synthesis of PIPs at the plasma membrane
  • Metabolism of lipids and lipoproteins
  • Phospholipid metabolism
  • PI Metabolism
ARF5 and ARFIP2 ADP-ribosylation factor 5 ADP-ribosylation factor interacting protein 2
ARF6 and AP3S2 ADP-ribosylation factor 6 adaptor-related protein complex 3, sigma 2 subunit
RHOA and MPRIP ras homolog family member A myosin phosphatase Rho interacting protein
  • Loss of Function of TGFBR2 in Cancer
  • Signaling by GPCR
  • Axon guidance
  • Axonal growth stimulation
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Signaling by Wnt
  • TGFBR1 LBD Mutants in Cancer
  • VEGFA-VEGFR2 Pathway
  • EPHB-mediated forward signaling
  • Rho GTPase cycle
  • EPHA-mediated growth cone collapse
  • Axonal growth inhibition (RHOA activation)
  • PI3K/AKT activation
  • G beta:gamma signalling through PI3Kgamma
  • EPH-Ephrin signaling
  • G alpha (12/13) signalling events
  • Sema4D mediated inhibition of cell attachment and migration
  • Sema4D in semaphorin signaling
  • Sema4D induced cell migration and growth-cone collapse
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • Signalling by NGF
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • p75NTR regulates axonogenesis
  • G-protein beta:gamma signalling
  • Loss of Function of SMAD2/3 in Cancer
  • Semaphorin interactions
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • p75 NTR receptor-mediated signalling
  • TGFBR1 KD Mutants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Loss of Function of TGFBR1 in Cancer
  • beta-catenin independent WNT signaling
  • GPCR downstream signaling
  • Signaling by TGF-beta Receptor Complex
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by VEGF
  • Signaling by Rho GTPases
  • GPVI-mediated activation cascade
  • Platelet activation, signaling and aggregation
  • PCP/CE pathway
  • SMAD4 MH2 Domain Mutants in Cancer
  • Guanosine-5\'-Diphosphate
RND3 and SKP2 Rho family GTPase 3 S-phase kinase-associated protein 2, E3 ubiquitin protein ligase
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Antigen processing: Ubiquitination & Proteasome degradation
  • G1 Phase
  • S Phase
  • Cyclin E associated events during G1/S transition
  • APC/C-mediated degradation of cell cycle proteins
  • Cell Cycle, Mitotic
  • SCF(Skp2)-mediated degradation of p27/p21
  • Cyclin D associated events in G1
  • G1/S Transition
  • Regulation of mitotic cell cycle
  • Class I MHC mediated antigen processing & presentation
  • Cyclin A:Cdk2-associated events at S phase entry
  • SCF(Skp2)-mediated degradation of p27/p21
  • Mitotic G1-G1/S phases
  • Adaptive Immune System
RND3 and CIT Rho family GTPase 3 citron rho-interacting serine/threonine kinase
RND3 and ARHGAP5 Rho family GTPase 3 Rho GTPase activating protein 5
  • Rho GTPase cycle
  • Signaling by Rho GTPases

Page 38 out of 155 pages